Optimal drug and behavior therapy for treatment-refractory schizophrenic patients

Robert Paul Liberman, Theodore Van Putten, Barringer D. Marshall, Jim Mintz, Linda Bowen, Timothy G. Kuehnel, Manickan Aravagiri, Stephen R. Marder

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Thirteen treatment-refractory schizophrenic patients (10 men and three women) who were receiving more than 50 mg/day of haloperidol and who had been hospitalized for more than 1 year successfully tolerated a mean dose reduction of 63% with consequent improvement in psychopathology and side effects. The addition of intensive behavior therapy to the optimal dose of haloperidol yielded further improvements in functional behavior, such as self-care and social interaction.

Original languageEnglish (US)
Pages (from-to)756-759
Number of pages4
JournalAmerican Journal of Psychiatry
Volume151
Issue number5
DOIs
StatePublished - May 1994
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Liberman, R. P., Van Putten, T., Marshall, B. D., Mintz, J., Bowen, L., Kuehnel, T. G., Aravagiri, M., & Marder, S. R. (1994). Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. American Journal of Psychiatry, 151(5), 756-759. https://doi.org/10.1176/ajp.151.5.756